621 related articles for article (PubMed ID: 28079788)
1. The prevalence of factor VIII and IX inhibitors among Saudi patients with hemophilia: Results from the Saudi national hemophilia screening program.
Owaidah T; Momen AA; Alzahrani H; Almusa A; Alkasim F; Tarawah A; Nouno RA; Batniji FA; Alothman F; Alomari A; Abu-Herbish S; Abu-Riash M; Siddiqui K; Ahmed M; Mohamed SY; Saleh M
Medicine (Baltimore); 2017 Jan; 96(2):e5456. PubMed ID: 28079788
[TBL] [Abstract][Full Text] [Related]
2. Hemophilia with factor VIII and factor IX inhibitors, incidence, bleeding problems and management.
Mahasandana C; Patharathienskul D; Suvatte V
Southeast Asian J Trop Med Public Health; 1993; 24 Suppl 1():106-12. PubMed ID: 7886549
[TBL] [Abstract][Full Text] [Related]
3. Relation of factor VIII and IX inhibitors with ABO blood groups in 150 patients with haemophilia A and B.
Torghabeh HM; Pourfathollah A; Shooshtari MM; Yazdi ZR
Iran J Allergy Asthma Immunol; 2006 Mar; 5(1):33-4. PubMed ID: 17242502
[TBL] [Abstract][Full Text] [Related]
4. Combined factor VIII and IX inhibitors in a non-haemophilic patient: successful treatment with immunosuppressive drugs.
Carmassi F; Giannarelli C; De Giorgi A; De Negri F
Haemophilia; 2007 Jan; 13(1):106-7. PubMed ID: 17212735
[TBL] [Abstract][Full Text] [Related]
5. Prophylactic factor replacement in hemophilia.
Carcao MD; Aledort L
Blood Rev; 2004 Jun; 18(2):101-13. PubMed ID: 15010149
[TBL] [Abstract][Full Text] [Related]
6. [Hemophiliacs with inhibitor. Experience at the Center of Medical Action for Hemophilia of the S. José Hospital].
Diniz MJ; Dias Francisco F; Tavares ML; Leal I
Acta Med Port; 1992 Apr; 5(4):178-80. PubMed ID: 1605065
[TBL] [Abstract][Full Text] [Related]
7. [Prophylaxis in patients with haemophilia complicated by inhibitors].
Paweł Ł
Pol Merkur Lekarski; 2011 Mar; 30(177):211-4. PubMed ID: 21545000
[TBL] [Abstract][Full Text] [Related]
8. FVIII and FIX inhibitors in people living with hemophilia in Cameroon, Africa: a preliminary study.
Balôgôg PN; Tagny CT; Ndoumba A; Mbanya D
Int J Lab Hematol; 2014 Oct; 36(5):566-70. PubMed ID: 25356499
[TBL] [Abstract][Full Text] [Related]
9. Immunosuppressive treatment in haemophiliacs with inhibitors to factor VIII and factor IX.
Nilsson IM; Hedner U
Scand J Haematol; 1976 May; 16(5):369-82. PubMed ID: 951577
[TBL] [Abstract][Full Text] [Related]
10. Surgical experience with rFVIIa (NovoSeven) in congenital haemophilia A and B patients with inhibitors to factors VIII or IX.
Valentino LA; Cooper DL; Goldstein B
Haemophilia; 2011 Jul; 17(4):579-89. PubMed ID: 21294815
[TBL] [Abstract][Full Text] [Related]
11. [The occurrence of immunological tolerance to inhibitors of factors VIII and IX in hemophilia patients].
Brakman GG
Gematol Transfuziol; 1993 Feb; 38(2):18-20. PubMed ID: 8020714
[TBL] [Abstract][Full Text] [Related]
12. Modification of the Bethesda assay for factor VIII or IX inhibitors to improve efficiency.
Gadarowski JJ; Czapek EE; Ontiveros JD; Pedraza JL
Acta Haematol; 1988; 80(3):134-8. PubMed ID: 3143212
[TBL] [Abstract][Full Text] [Related]
13. Inhibitor antibodies to factor VIII and factor IX: management.
Lusher JM
Semin Thromb Hemost; 2000; 26(2):179-88. PubMed ID: 10919411
[TBL] [Abstract][Full Text] [Related]
14. Decline of factor VIII and factor IX inhibitors during long-term treatment with NovoSeven.
Johannessen M; Andreasen RB; Nordfang O
Blood Coagul Fibrinolysis; 2000 Apr; 11(3):239-42. PubMed ID: 10870803
[TBL] [Abstract][Full Text] [Related]
15. The evolution of recombinant factor replacement for hemophilia.
Sankar AD; Weyand AC; Pipe SW
Transfus Apher Sci; 2019 Oct; 58(5):596-600. PubMed ID: 31421983
[TBL] [Abstract][Full Text] [Related]
16. Frequency of specific coagulation inhibitors and antiphospholipid antibodies in Tunisian haemophiliacs.
Kraiem I; Hadhri S; El Omri H; Sassi R; Chaabani W; Ennabli S; Skouri H
Ann Biol Clin (Paris); 2012; 70(6):659-65. PubMed ID: 23207810
[TBL] [Abstract][Full Text] [Related]
17. Adherence to clotting factors among persons with hemophilia A or B.
Armstrong EP; Malone DC; Krishnan S; Wessler MJ
Hematology; 2015 Apr; 20(3):148-53. PubMed ID: 25001343
[TBL] [Abstract][Full Text] [Related]
18. Is the Detection of Factor IX Inhibitors in Hemophilia B Orphan than Factor VIII Inhibitors in Hemophilia A? A Concise, Systematic Review.
Mansouritorghabeh H; Mohades ST
Cardiovasc Hematol Disord Drug Targets; 2020; 20(3):185-190. PubMed ID: 32611303
[TBL] [Abstract][Full Text] [Related]
19. The management of musculoskeletal problems in hemophilia. Part I. Principles of medical management of hemophilia.
McMillan CW; Greene WB; Blatt PM; White GC; Roberts HR
Instr Course Lect; 1983; 32():210-6. PubMed ID: 6443730
[TBL] [Abstract][Full Text] [Related]
20. Induction of immune tolerance in hemophiliacs with inhibitors by combined treatment with i.v. IgG, cyclophosphamide and factor VIII or IX.
Nilsson IM; Berntorp E
Prog Clin Biol Res; 1990; 324():69-78. PubMed ID: 2106694
[No Abstract] [Full Text] [Related]
[Next] [New Search]
